Search Results
Sep 08, 2026, 09:15 ET Altesa BioSciences Presents Novel Clinical Data Demonstrating Vapendavir Significantly Reduces Key Inflammatory Biomarkers in Rhinovirus-Challenged COPD Patients at the European Respiratory Society International Congress 2026
inflammatory molecules — IP-10/CXCL10 and GM-CSF — over the course of infection compared to placebo. Nasal levels of two additional biomarkers, IFN-α2a and IFN-λ1/IL-29, trended lower with vapendavir treatment but did not reach statistical significance."The data collectively support a mechanistic link
More news about: Altesa Biosciences Inc.
Aug 19, 2026, 10:31 ET Checkpoint Inhibitor Refractory Cancer Market Outlook is Predicted to Improve by 2036, Biopharma Companies Advance Novel Immuno-Oncology Candidates | DelveInsight
from the bloodstream into tumor tissue. This activation initiates a broader immune response through the release of pro-inflammatory cytokines, such as IFN-γ and TNF-α, thereby amplifying antitumor immune activity. Clinical studies have demonstrated antitumor efficacy across multiple cancer indications.
More news about: DelveInsight Business Research, LLP
Aug 11, 2026, 16:17 ET Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
abrdn U.S. Closed-End Funds (NYSE: ACP, AGD, AOD, ASGI, AWP, HQH, HQL, IFN, MFM, MGF, MIN, MMT, THQ, THW and NYSE American: FAX, IAF), announced today that the closed end funds in the chart directly below will pay the distributions
More news about: Aberdeen Investments U.S. Closed End Funds
Jul 09, 2026, 10:31 ET Systemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsight
production of inflammatory mediators. By binding to BDCA2, litifilimab suppresses pDC activation, thereby reducing the release of type I interferons (IFN-I) along with other proinflammatory cytokines and chemokines implicated in SLE pathogenesis.Biogen is currently evaluating litifilimab in two global
More news about: DelveInsight Business Research, LLP
Jun 30, 2026, 16:17 ET Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
Aberdeen Investments U.S. Closed-End Funds (NYSE: ASGI, HQH, HQL, IFN, THQ, THW), (NYSE American: IAF) (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below
More news about: Aberdeen Investments U.S. Closed End Funds
Jun 23, 2026, 10:31 ET Non-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsight
present in the tumor or cyst microenvironment, leading to a pro-inflammatory response characterized by the release of cytokines such as TNF-alpha, IFN-gamma, IL-6, IL-10, and IL-12. In addition to directly destroying tumor cells, TARA-002 promotes immunogenic cell death, further amplifying the body's antitumor
More news about: DelveInsight Business Research, LLP
Jun 10, 2026, 15:01 ET Children's Hospital of Philadelphia Study May Help Explain Why Some Children with Sepsis or Organ Failure Face a Harder Recovery
the highest risk. These children showed an extreme inflammatory response marked by high activity of both interleukin‑6 (IL‑6) and interferon-gamma (IFN-γ), immune signals that help coordinate the body's response to infection or injury. When these signals are too strong or persist for too long, they can
More news about: Children's Hospital of Philadelphia
Jun 07, 2026, 20:00 ET Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance
bowel disease model. In human whole blood assays, ATG-207 induced minimal production of pro-inflammatory cytokines, including IL-2, IL-6, TNF-α, and IFN-γ.Conclusion: ATG-207 represents a differentiated immune tolerance–restoring strategy that integrates precision T cell targeting, context-restricted
More news about: Antengene Corporation Limited
Jun 05, 2026, 12:30 ET Altesa BioSciences Presents New Phase 2 Vapendavir Challenge Study Results at 2026 American Society for Microbiology (ASM) Microbe Conference
mediators consistent with a desired innate antiviral response, including IFN-α2a, IL-29, IP-10, and GM-CSF. Compared to placebo, vapendavir treatment reduced key inflammatory mediators, including:Peak IFN-α2a levels by approximately 38%Peak IP-10 levels by approximately
More news about: Altesa Biosciences Inc.
May 27, 2026, 18:39 ET ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE RESULTS OF ANNUAL MEETING OF SHAREHOLDERS
788,738Aberdeen India Fund, Inc. ("IFN")As of the record date, April 1, 2026, IFN had outstanding 42,651,950 shares of common stock. 65.74% of outstanding common stock were voted representing a quorum.To
More news about: Aberdeen Investments U.S. Closed End Funds
May 20, 2026, 08:56 ET Pictor and Disease Research Limited Formalise Collaboration to Advance Johne's Disease Monitoring Across New Zealand
Multiplex biomarker-based ELISA enables early detection of Mycobacterium avium subspecies paratuberculosis-specific antibodies comparable to IFN-γ testing. Front Vet Sci. 2025. doi:10.3389/fvets.2025.1749510Photo -
More news about: Pictor Holdings Inc.
May 20, 2026, 08:56 ET Pictor and Disease Research Limited Formalise Collaboration to Advance Johne's Disease Monitoring Across New Zealand
Multiplex biomarker-based ELISA enables early detection of Mycobacterium avium subspecies paratuberculosis-specific antibodies comparable to IFN-γ testing. Front Vet Sci. 2025. doi:10.3389/fvets.2025.1749510
More news about: Pictor Holdings Inc.
May 20, 2026, 03:00 ET Greenberg Traurig's Capital Markets Practice Recognized Across Five Winning Deals of the Year at Islamic Finance News Awards 2025
will continue to grow rapidly as structures evolve and the popularity of these instruments reaches new markets," Roussos said.The IFN Awards follow on from the IFN KSA Dialogues 2025 event on Nov. 19, 2025, where Ahmed and Roussos featured as panellists discussing "Shaping the Future: Islamic Investment
More news about: Greenberg Traurig, LLP
May 11, 2026, 16:17 ET Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
Inc. (IFN) will pay their distributions on June 30, 2026, to shareholders of record as of May 21, 2026 (ex‑dividend date May 21, 2026).For abrdn Healthcare Investors (HQH), the abrdn Life Sciences Investors (HQL), the abrdn Australia Equity Fund, Inc. (IAF) and the India Fund, Inc. (IFN), this
More news about: Aberdeen Investments U.S. Closed End Funds
May 01, 2026, 09:00 ET Diakonos Oncology Reports Positive Clinical Data from Phase 1 Pancreatic Cancer Study and Expanded Access Program in Glioblastoma at AACR and AAN 2026
symptoms, including headache, fatigue, chills, and fever; no dose-limiting toxicities (DLTs) observed.Increased granzyme B in CD8+ T cells and IFN-γ in CD4+ effector memory T cells, indicating enhanced cytotoxic functionality.Increased CD127 expression was observed on circulating CD8+ and
More news about: Diakonos Oncology
Apr 20, 2026, 06:07 ET Immunofoco Presents Preclinical Data for IMV102, an In Vivo CAR-T Candidate, Demonstrating Durable Tumor Control at the AACR 2026
IMV102-generated CAR-T cells exhibited potent cytotoxic activity against NCI-H929 multiple myeloma cells, accompanied by significant upregulation of IFN-γ.In vivo, IMV102 induced CAR-T cell generation and achieved potent and durable tumor inhibition in two multiple myeloma xenograft models (H929-Luc
More news about: Immunofoco
Apr 17, 2026, 20:30 ET Antengene Presents Three Novel Programs at AACR 2026, Highlighting Next-Generation ADC and AnTenGager® TCEs
intracellular payload release. The molecule induced tumor cell apoptosis, while its parental naked antibody blocked PD-1/PD-L1 interaction and elicited IL-2 and IFN-γ production in mixed lymphocyte reaction assays. ATG-125 also enhanced T-cell activation, as reflected by an increased ratio of CD69+/CD3+ T cells in
More news about: Antengene Corporation Limited
Mar 31, 2026, 16:17 ET Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
Aberdeen Investments U.S. Closed-End Funds (NYSE: ASGI, HQH, HQL, IFN, THQ), (NYSE American: IAF) (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below
More news about: Aberdeen Investments U.S. Closed End Funds
Mar 18, 2026, 07:44 ET Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026
HER2 biology, emerging pre-clinical data on dordaviprone and related imipridones, and advancing research on JZP898, a conditionally activated IFN⍺2b cytokine For U.S. media and investors onlyDUBLIN, March
More news about: Jazz Pharmaceuticals plc
Mar 07, 2026, 17:51 ET TTW Picks Best 50 Heritage Travel Destinations in the World for 2026
International Airport (BXR)Masjed-e Jame of Isfahan (Jame Mosque) – Isfahan International Airport (IFN)Meidan Emam, Esfahan – Isfahan International Airport (IFN)Shushtar Historical Hydraulic System – Ahvaz Airport (AWZ)21. Portugal – A Blend
More news about: Travel And Tour World
Feb 12, 2026, 16:17 ET The India Fund, Inc. (IFN) Announces Name Change
The India Fund, Inc. (IFN) has approved a name change for the Fund, to be effective February 27, 2026, as set forth below.
More news about: The India Fund, Inc.
Feb 10, 2026, 16:17 ET Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
Inc. (IFN) which will pay on March 31, 2026, to all shareholders of record as of February 20, 2026 (ex-dividend date February 20, 2026).For abrdn Healthcare Investors (HQH), the abrdn Life Sciences Investors (HQL), the abrdn Australia Equity Fund, Inc. (IAF) and the India Fund, Inc. (IFN), this
More news about: Aberdeen Investments U.S. Closed End Funds
Jan 13, 2026, 17:31 ET Macrophage Activation Syndrome Market in the 6MM to Witness Upsurge in Growth at a CAGR of 24.7% During the Forecast Period (2025-2034) | DelveInsight
(Novartis), and others.Advances in Targeted Immunomodulatory Drug Classes: Novel drug classes, including JAK inhibitors, anti-IFN antibodies, and IL-1/IL-6 blockers, represent opportunities for differentiated, targeted treatments.Macrophage Activation Syndrome
More news about: DelveInsight Business Research, LLP
Jan 12, 2026, 16:17 ET Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
Aberdeen Investments U.S. Closed-End Funds (NYSE: ASGI, HQH, HQL, IFN, THQ), (NYSE American: IAF), (the "Funds" or individually the "Fund"), today announced that the Funds paid the distributions noted in the table below
More news about: Aberdeen Investments U.S. Closed End Funds
Jan 07, 2026, 17:31 ET Psoriasis Market to Exhibit Growth at a CAGR of 1.7% During the Forecast Period (2025-2034), Owing to Continuous Innovation in Biologic Therapies and Approval of Oral Small Molecules | DelveInsight
Can-Fite BioPharma (piclidenoson; A3 Adenosine Receptor [A3AR] agonist) and SFA Therapeutics (SFA-002; TNF-α, IL-23, IL-10, IL-12, IL-17, and IFN-γ inhibitor) are conducting late-stage trials for the treatment of psoriasis. With unique MoAs, these therapies hold an opportunity to stand out.Takeda's
More news about: DelveInsight Business Research, LLP